The HOPE4MCI study: AGB101 treatment reduces entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer’s Disease who are ApoE‐4 non‐carriers

Nisha Rani, Richard Mohs, Michela Gallagher, Arnold Bakker · 2025

Read The HOPE4MCI study: AGB101 treatment reduces entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer’s Disease who are ApoE‐4 non‐carriers by Nisha Rani, Richard Mohs, Michela Gallagher, Arnold Bakker (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715270.txt.

Description

Nisha Rani and co-authors report brain scan results from the HOPE4MCI trial of AGB101, a slow-release form of a known seizure drug, in early Alzheimer's disease. The drug calms an overactive hippocampus, a trait that forecasts decline in amnestic mild cognitive impairment. Earlier reports covered thinking scores; this one covers tissue change.

The scan study covers forty-four trial finishers who lack the ApoE-4 gene variant, tracked over seventy-eight weeks. Treated patients lost less tissue in the left entorhinal cortex, a memory hub hit early by the disease. That saving tracked closely with steadier daily-function scores. Blood markers drawn at the final visit join the scan story. The results back a gene-guided view of who gains most from the drug.

Catalog record

CREATORNisha Rani, Richard Mohs, Michela Gallagher, Arnold Bakker
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11715270

Browse the full library · About the Tower of Babel